Royce & Associates LP held its position in shares of Repligen Corporation (NASDAQ:RGEN) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 70,000 shares of the biotechnology company’s stock at the close of the second quarter. Royce & Associates LP owned approximately 0.21% of Repligen Corporation worth $2,901,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Benin Management CORP purchased a new position in Repligen Corporation during the second quarter worth about $207,000. Jennison Associates LLC purchased a new position in Repligen Corporation during the second quarter worth about $291,000. Karp Capital Management Corp purchased a new position in Repligen Corporation during the first quarter worth about $506,000. Invictus RG purchased a new position in Repligen Corporation during the first quarter worth about $233,000. Finally, Geode Capital Management LLC lifted its position in Repligen Corporation by 8.2% during the first quarter. Geode Capital Management LLC now owns 323,737 shares of the biotechnology company’s stock worth $11,395,000 after buying an additional 24,591 shares during the period. Hedge funds and other institutional investors own 97.91% of the company’s stock.
Several research firms recently weighed in on RGEN. BidaskClub upgraded Repligen Corporation from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 24th. Janney Montgomery Scott upped their price target on Repligen Corporation from $42.00 to $47.00 in a research note on Friday, June 23rd. Jefferies Group LLC restated a “hold” rating and set a $40.00 price target (up from $33.00) on shares of Repligen Corporation in a research note on Wednesday, June 28th. William Blair began coverage on Repligen Corporation in a research note on Friday, July 21st. They set an “outperform” rating for the company. Finally, TheStreet upgraded Repligen Corporation from a “c+” rating to a “b-” rating in a research note on Friday, August 11th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $42.00.
Shares of Repligen Corporation (NASDAQ RGEN) opened at 43.45 on Monday. The firm’s 50-day moving average price is $41.81 and its 200 day moving average price is $38.29. Repligen Corporation has a 52 week low of $26.16 and a 52 week high of $46.81. The firm has a market capitalization of $1.62 billion, a price-to-earnings ratio of 85.03 and a beta of 1.21.
Repligen Corporation (NASDAQ:RGEN) last released its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.15 by $0.05. The firm had revenue of $32.40 million during the quarter, compared to analysts’ expectations of $31.72 million. Repligen Corporation had a return on equity of 9.90% and a net margin of 15.61%. The business’s revenue for the quarter was up 11.0% on a year-over-year basis. During the same quarter last year, the firm earned $0.16 earnings per share. On average, analysts anticipate that Repligen Corporation will post $0.59 EPS for the current year.
Repligen Corporation Company Profile
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.
Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Corporation (NASDAQ:RGEN).
Receive News & Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related companies with MarketBeat.com's FREE daily email newsletter.